匹妥布替尼治疗共价布鲁顿酪氨酸激酶抑制剂经治的套细胞淋巴瘤
在BRUIN多中心I/II期试验中,共价BTK抑制剂经治的复发/难治套细胞淋巴瘤患者接受匹妥布替尼单药治疗,前90例可评估患者总缓解率为57.8%(95%CI 46.9-68.1),完全缓解率20.0%;中位随访12个月时中位缓解持续时间21.6个月(95%CI 7.5-未达到),安全性队列(n=164)因治疗相关不良事件停药者仅3%。
要点
- 匹妥布替尼在共价BTK抑制剂经治的复发/难治套细胞淋巴瘤中总缓解率57.8%,完全缓解率20.0%。
- 中位随访12个月时中位缓解持续时间21.6个月,6个月和12个月估计缓解持续时间率分别为73.6%和57.1%。
- 安全性队列最常见治疗中出现的不良事件为疲乏(29.9%)、腹泻(21.3%)和呼吸困难(16.5%),因治疗相关不良事件停药仅3%。
核心结论
- 匹妥布替尼是首创的非共价(可逆)BTK抑制剂,也是首个在共价BTK抑制剂经治的重度预处理复发/难治套细胞淋巴瘤中显示持久疗效的BTK抑制剂。
- 匹妥布替尼耐受性良好,因毒性停药率低。
研究设计与样本
- 多中心I/II期试验(BRUIN;ClinicalTrials.gov标识符NCT03740529)。
- 共价BTK抑制剂经治的复发/难治套细胞淋巴瘤患者接受匹妥布替尼单药治疗。
- 疗效在符合主要疗效队列入选标准的前90例连续入组患者中评估。
- 主要终点为总缓解率,次要终点包括缓解持续时间和安全性。
主要发现
- 患者中位年龄70岁(范围46-87),中位既往治疗线数3线(范围1-8)。
- 82.2%的患者因疾病进展停用既往共价BTK抑制剂,77.8%的患者简化套细胞淋巴瘤国际预后指数评分为中危或高危。
- 总缓解率为57.8%(95%CI 46.9-68.1),包括20.0%的完全缓解(n=18)。
- 中位随访12个月时,中位缓解持续时间为21.6个月(95%CI 7.5-未达到),6个月和12个月估计缓解持续时间率分别为73.6%和57.1%。
- 安全性队列(n=164)最常见治疗中出现的不良事件为疲乏(29.9%)、腹泻(21.3%)和呼吸困难(16.5%);≥3级出血(3.7%)和房颤/房扑(1.2%)较少见;仅3%的患者因治疗相关不良事件停用匹妥布替尼。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (MCL), a population with poor prognosis. METHODS: Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter phase I/II trial (BRUIN; ClinicalTrials.gov identifier: NCT03740529). Efficacy was assessed in the first 90 consecutively enrolled patients who met criteria for inclusion in the primary efficacy cohort. The primary end point was overall response rate (ORR). Secondary end points included duration of response (DOR) and safety. RESULTS: The median patient age was 70 years (range, 46-87), the median prior lines of therapy was 3 (range, 1-8), 82.2% had discontinued a prior cBTKi because of disease progression, and 77.8% had intermediate- or high-risk simplified MCL International Prognostic Index score. The ORR was 57.8% (95% CI, 46.9 to 68.1), including 20.0% complete responses (n = 18). At a median follow-up of 12 months, the median DOR was 21.6 months (95% CI, 7.5 to not reached). The 6- and 12-month estimated DOR rates were 73.6% and 57.1%, respectively. In the MCL safety cohort (n = 164), the most common treatment-emergent adverse events (TEAEs) were fatigue (29.9%), diarrhea (21.3%), and dyspnea (16.5%). Grade ≥3 TEAEs of hemorrhage (3.7%) and atrial fibrillation/flutter (1.2%) were less common. Only 3% of patients discontinued pirtobrutinib because of a treatment-related adverse event. CONCLUSION: Pirtobrutinib is a first-in-class novel noncovalent (reversible) BTKi and the first BTKi of any kind to demonstrate durable efficacy after prior cBTKi therapy in heavily pretreated R/R MCL. Pirtobrutinib was well tolerated with low rates of treatment discontinuation because of toxicity.
引用
- Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023. PMID: 37192437. doi:10.1200/JCO.23.00562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。